SCHEMBL1008300

SCHEMBL1008300

O=C(O)C(CC1CCOCC1)n1ncc(Oc2ccccc2Cl)c(Cl)c1=O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GCK P35557 7/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
ATM Q13315 1/20 0.36
CAMK2A Q9UQM7 1/20 0.35
CXCL8 P10145 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LDHA P00338 1/20 0.34
FFAR2 O15552 1/20 0.34
MAPK8 P45983 1/20 0.34
F11 P03951 1/20 0.34
KLKB1 P03952 1/20 0.34
PDE9A O76083 1/20 0.34
LPAR1 Q92633 1/20 0.33
LPAR5 Q9H1C0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008715 0.85 LPAR1 (0.37) GCKHPGDSMN1; SMN2ALDH1A1LDHA
SCHEMBL1008644 0.81 NPY5R (0.39) SMN1; SMN2LMNAHTTATMALDH1A1
SCHEMBL1064590 0.79 GCK (0.48) GCKHPGDSMN1; SMN2LMNAHTT
SCHEMBL1010867 0.75 FFAR4 (0.37) ALDH1A1
SCHEMBL1008502 0.74 PREP (0.41) GCKHPGD
SCHEMBL1008225 0.72 LMNA (0.36) GCKHPGDSMN1; SMN2LMNAHTT
SCHEMBL1008584 0.71 HIF1A (0.36) GCKALDH1A1
SCHEMBL1008851 0.70 GRN (0.38) GCKSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL1008521 0.69 GCK (0.38) GCKPDE9ALPAR1LPAR5
SCHEMBL1064688 0.68 GCK (0.48) GCKF11KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK GCK 1/4885HPGD 597/4885SMN1; SMN2 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.